Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?

References

• Iacovino LG, Magnani F, Binda C. The structure of monoamine oxidases: past, present, and future. J Neural Transm. 2018;125:1567–1579.
   PubMed Web of Science ®Google Scholar
• Tipton KF. 90 years of monoamine oxidase: some progress and some confusion. J Neural Transm. 2018;125:1519–1551.
   PubMed Web of Science ®Google Scholar
• Youdim MBH. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J Neural Transm. 2018;125:1719–1733.
   PubMed Web of Science ®Google Scholar
• Binde CD, Tvete IF, Gåsemyr J, et al. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br J Clin Pharmacol. 2018;84:1917–1927.
   PubMed Web of Science ®Google Scholar
• Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm. 2018;125:1707–1717.
   PubMed Web of Science ®Google Scholar
• Bette S, Shpiner DS, Singer C, et al. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag. 2018;14:1737–1745.
   PubMed Web of Science ®Google Scholar
• Kabra A, Sharma R, Kabra R, et al. Emerging and alternative therapies for Parkinson disease: an updated review. Curr Pharm Des. 2018;24:2573–2582.
   PubMed Web of Science ®Google Scholar
• Carradori S, Silvestri R. New frontiers in selective human MAO-B inhibitors. J Med Chem. 2015;58:6717–6732.
   PubMed Web of Science ®Google Scholar
• Carradori S, Secci D, Petzer JP. MAO inhibitors and their wider applications: a patent review. Expert Opin Ther Pat. 2018;28:211–226.
   PubMed Web of Science ®Google Scholar
• Carradori S, Petzer JP. Novel monoamine oxidase inhibitors: a patent review (2012–2014). Expert Opin Ther Pat. 2015;25:91–110.
   PubMed Web of Science ®Google Scholar
• Carradori S, Secci D, Bolasco A, et al. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin Ther Pat. 2012;22:759–801.
   PubMed Web of Science ®Google Scholar
• Bolasco A, Carradori S, Fioravanti R. Focusing on new monoamine oxidase inhibitors. Expert Opin Ther Pat. 2010;20:909–939.
   PubMed Web of Science ®Google Scholar
• Bolasco A, Fioravanti R, Carradori S. Recent development of monoamine oxidase inhibitors. Expert Opin Ther Pat. 2005;15:1763–1782.
   Web of Science ®Google Scholar
• Xie S, Chen J, Li X, et al. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer’s disease. Bioorg Med Chem. 2015;23:3722–3729.
   PubMed Web of Science ®Google Scholar
• Gealageas R, Devineau A, So PPL, et al. Development of novel monoamine oxidase-B (MAO-B) inhibitors with reduced blood−brain barrier permeability for the potential management of noncentral nervous system (CNS) diseases. J Med Chem. 2018;61:7043−64.
   PubMed Web of Science ®Google Scholar
• Nag S, Fazio P, Lehmann L, et al. In vivo and in vitro characterization of a novel MAO-B inhibitor radioligand, 18F-labeled deuterated fluorodeprenyl. J Nucl Med. 2016;57:315–320.
   PubMed Web of Science ®Google Scholar
• Malcomson T, Yelekci K, Borrello MT, et al. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases. Febs J. 2015;282:3190–3198.
   PubMed Web of Science ®Google Scholar
• Liu Z, Cai W, Lang M, et al. Neuroprotective effects and mechanisms of action of multifunctional agents targeting free radicals, monoamine oxidase B and cholinesterase in Parkinson’s disease model. J Mol Neurosci. 2017;61:498–510.
   PubMed Web of Science ®Google Scholar
• Youdim MB. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol. 2013;22:1–10.
   PubMedGoogle Scholar
• Floyd RA, Kopke RD, Choi CH, et al. Nitrones as therapeutics. Free Radic Biol Med. 2008;45:1361–1374.
   PubMed Web of Science ®Google Scholar
• Marco-Contelles J, Unzeta M, Bolea I, et al. ASS234, as a new multi-target directed propargylamine for Alzheimer’s disease therapy. Front Neurosci. 2016;10:294.
   PubMed Web of Science ®Google Scholar
• Bolea I, Colivicchi MA, Ballini C, et al. Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an in vivo model of excitotoxicity. CNS Neurosci Ther. 2014;20:641–650.
   PubMed Web of Science ®Google Scholar
• Bautista-Aguilera OM, Esteban G, Chioua M, et al. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. Drug Des Devel Ther. 2014;8:1893–1910.
   PubMed Web of Science ®Google Scholar
• Shaik AN, LeDuc BW, Khan AA. Characterization of 1-aminobenzotriazole and ketoconazole as novel inhibitors of monoamine oxidase (MAO): an in vitro investigation. Eur J Drug Metab Pharmacokinet. 2017;42:827–834.
   PubMed Web of Science ®Google Scholar
• Barkhuizen M, Petzer A, Petzer JP. The inhibition of monoamine oxidase by phenformin and pentamidine. Drug Res. 2014;64:454–461.
   Google Scholar
• Mathew B, Uçar G, Mathew GE, et al. Monoamine oxidase inhibitory activity: methyl- versus chlorochalcone derivatives. ChemMedChem. 2016;11:2649–2655.
   PubMed Web of Science ®Google Scholar
• Mathew B, Mathew GE, Uçar G, et al. Monoamine oxidase inhibitory activity of methoxy-substituted chalcones. Int J Biol Macromol. 2017;104:1321–1329.
   PubMed Web of Science ®Google Scholar
• Choi JW, Jang BK, Cho N-C, et al. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg Med Chem. 2015;23:6486–6496.
   PubMed Web of Science ®Google Scholar
• Engelbrecht I, Petzer JP, Petzer A. Nitrocatechol derivatives of chalcone as inhibitors of monoamine oxidase and Catechol-O-Methyltransferase. Cent Nerv Syst Agents Med Chem. 2018;18:115–127.
   PubMedGoogle Scholar
• Hammuda A, Shalaby R, Rovida S, et al. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. Eur J Med Chem. 2016;114:162–169.
   PubMed Web of Science ®Google Scholar
• Mathew B, Mathew GE, Ucar G, et al. Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: synthesis, biochemistry and molecular docking studies. Bioorg Chem. 2015;62:22–29.
   PubMed Web of Science ®Google Scholar
• Mathew B, Mathew GE, Uçar G, et al. Potent and selective monoamine oxidase-B inhibitory activity: fluoro- vs. trifluoromethyl-4-hydroxylated chalcone derivatives. Chem Biodivers. 2016;13:1046–1052.
   PubMed Web of Science ®Google Scholar
• Mathew B, Baek SC, Thomas Parambi DG, et al. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: fluorinated chalcones of morpholine versus imidazole. Arch Pharm Chem Life Sci. 2019;352:e1800309.
   PubMed Web of Science ®Google Scholar
• Mathew B, Haridas A, Uçar G, et al. Exploration of chlorinated thienyl chalcones: a new class of monoamine oxidase-B inhibitors. Int J Biol Macromol. 2016;91:680–695.
   PubMed Web of Science ®Google Scholar
• Sasidhara R, Manju SL, Uçar G, et al. Identification of indole-based chalcones: discovery of a potent, selective, and reversible class of MAO-B inhibitors. Arch Pharm (Weinheim). 2016;349:627–637.
   PubMed Web of Science ®Google Scholar
• Suresh J, Baek SC, Ramakrishnan SP, et al. Discovery of potent and reversible MAO-B inhibitors as furanochalcones. Int J Biol Macromol. 2018;108:660–664.
   PubMed Web of Science ®Google Scholar
• Minders C, Petzer JP, Petzer A, et al. Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg Med Chem Lett. 2015;25:5270–5276.
   PubMed Web of Science ®Google Scholar
• Xiao G, Li Y, Qiang X, et al. Design, synthesis and biological evaluation of 4ʹ-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2017;25:1030–1041.
   PubMed Web of Science ®Google Scholar
• Nayak BV, Ciftci-Yabanoglu S, Bhakat S, et al. Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones. Bioorg Chem. 2015;58:72–80.
   PubMed Web of Science ®Google Scholar
• Takao K, Saito T, Chikuda D, et al. 2-Azolylchromone derivatives as potent and selective inhibitors of monoamine oxidases A and B. Chem Pharm Bull. 2016;64:1499–1504.
   PubMed Web of Science ®Google Scholar
• Reis J, Cagide F, Chavarria D, et al. Discovery of new chemical entities for old targets: insights on the lead optimization of chromone-based monoamine oxidase B (MAOB) inhibitors. J Med Chem. 2016;59:5879−93.
   PubMed Web of Science ®Google Scholar
• Mpitimpiti AN, Petzer JP, Petzer A, et al. Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase. Mol Divers. 2019. DOI:10.1007/s11030-019-09917-8.
   PubMedGoogle Scholar
• Mangiatordi GF, Alberga D, Pisani L, et al. A rational approach to elucidate human monoamine oxidase molecular selectivity. Eur J Pharm Sci. 2017;101:90–99.
   PubMed Web of Science ®Google Scholar
• Pachón-Angona I, Refouvelet B, Andrýs R, et al. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy. J Enzyme Inhib Med Chem. 2019;34:479–489.
   PubMed Web of Science ®Google Scholar
• Desideri N, Proietti ML, Fioravanti R, et al. (E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors. Eur J Med Chem. 2016;117:292–300.
   PubMed Web of Science ®Google Scholar
• Amakali KT, Legoabe LJ, Petzer A, et al. Synthesis and evaluation of 2-benzylidene-1-tetralone derivatives for monoamine oxidase inhibitory activity. Cent Nerv Syst Agents Med Chem. 2018;18:136–149.
   PubMedGoogle Scholar
• Li Y, Qiang X, Luo L, et al. Multitarget drug design strategy against Alzheimer’s disease: homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties. Bioorg Med Chem. 2017;25:714–726.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun Y, Guo Y, et al. Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives. J Enzyme Inhib Med Chem. 2016;31:389–397.
   PubMed Web of Science ®Google Scholar
• Pisani L, Farina R, Soto-Otero R, et al. Searching for multi-targeting neurotherapeutics against Alzheimer’s: discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-chromen-2-one structural motif. Molecules. 2016;21:362.
   PubMed Web of Science ®Google Scholar
• Liu Q-H, Wu -J-J, Li F, et al. Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer’s disease. Med Chem Commun. 2017;8:1459.
   Google Scholar
• Mattsson C, Svensson P, Sonesson C. hMAO-A inhibitors-A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors. Eur J Med Chem. 2014;73:177–186.
   PubMed Web of Science ®Google Scholar
• Xie -S-S, Wang X, Jiang N, et al. Kong. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer’s disease. Eur J Med Chem. 2015;95:153–165.
   PubMed Web of Science ®Google Scholar
• Xie -S-S, Lan J-S, Wang X, et al. Design, synthesis and biological evaluation of novel donepezil–coumarin hybrids as multi-target agents for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2016;24:1528–1539.
   PubMed Web of Science ®Google Scholar
• Farina R, Pisani L, Catto M, et al. Structure-based design and optimization of multitarget-directed 2H-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J Med Chem. 2015;58:5561−78.
   PubMed Web of Science ®Google Scholar
• Pisani L, Farina R, Catto M, et al. Exploring basic tail modifications of coumarin-based dual acetylcholinesterase-monoamine oxidase B inhibitors: identification of water-soluble, brain-permeant neuroprotective multitarget agents. J Med Chem. 2016;59:6791−806.
   PubMed Web of Science ®Google Scholar
• Lan J-S, Ding Y, Liu Y, et al. Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2017;139:48–59.
   PubMed Web of Science ®Google Scholar
• Joubert J, Foka GB, Repsold BP, et al. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem. 2017;125:853–864.
   PubMed Web of Science ®Google Scholar
• He Q, Liu J, Lan J-S, et al. Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: design, synthesis and biological evaluation. Bioorg Chem. 2018;81:512–528.
   PubMed Web of Science ®Google Scholar
• Repsold BP, Malan SF, Joubert J, et al. Multi-targeted directed ligands for Alzheimer’s disease: design of novel lead coumarin conjugates. SAR QSAR Environ Res. 2018;29:231–255.
   PubMed Web of Science ®Google Scholar
• Pisani L, Iacobazzi RM, Catto M, et al. Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. Eur J Med Chem. 2019;161:292–309.
   PubMed Web of Science ®Google Scholar
• Huang M, Xie -S-S, Jiang N, et al. Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer’s disease. Bioorg Med Chem Lett. 2015;25:508–513.
   PubMed Web of Science ®Google Scholar
• Costas-Lago MC, Besada P, Rodríguez-Enríquez F, et al. Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors. Eur J Med Chem. 2017;139:1–11.
   PubMed Web of Science ®Google Scholar
• Ruan B-F, Cheng H-J, Ren J, et al. Novel 2H-chromen-2-one derivatives of resveratrol: design, synthesis, modeling and use as human monoamine oxidase inhibitors. Eur J Med Chem. 2015;103:185–190.
   PubMed Web of Science ®Google Scholar
• Mladenović M, Patsilinakos A, Pirolli A, et al. Understanding the molecular determinant of reversible human monoamine oxidase B inhibitors containing 2H-chromen-2-one core: structure-based and ligand-based derived three-dimensional quantitative structure−activity relationships predictive models. J Chem Inf Model. 2017;57:787–814.
   PubMed Web of Science ®Google Scholar
• Kallitsakis MG, Yañez M, Soriano E, et al. Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer’s disease. Future Med Chem. 2015;7:103–110.
   PubMed Web of Science ®Google Scholar
• Kallitsakis MG, Carotti A, Catto M, et al. Synthesis and biological evaluation of novel hybrid molecules containing purine, coumarin and isoxazoline or isoxazole moieties. Open Med Chem J. 2017;11:196–211.
   PubMedGoogle Scholar
• Matos MJ, Janeiro P, González Franco RM, et al. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases. Future Med Chem. 2014;6:371–383.
   PubMed Web of Science ®Google Scholar
• Zindo FT, Joubert J, Malan SF. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond. Future Med Chem. 2015;7:609–629.
   PubMed Web of Science ®Google Scholar
• Huleatt PB, Khoo ML, Chua YY, et al. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson’s disease. J Med Chem. 2015;58:1400−19.
   PubMedGoogle Scholar
• Baranyi M, Porceddu PF, Gölöncsér F, et al. Novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease. Mol Neurodegener. 2016;11:6.
   PubMed Web of Science ®Google Scholar
• Košak U, Knez D, Coquelle N, et al. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer’s agents. Bioorg Med Chem. 2017;25:633–645.
   PubMed Web of Science ®Google Scholar
• Di Giovanni G, García I, Colangeli R, et al. N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): a potential cognitive enhancer with MAO inhibitor properties. CNS Neurosci Ther. 2014;20:633–640.
   PubMed Web of Science ®Google Scholar
• Kumar B, Kumar M, Dwivedi AR, et al. Synthesis, biological evaluation and molecular modeling studies of propargyl-containing 2,4,6-trisubstituted pyrimidine derivatives as potential anti-Parkinson agents. ChemMedChem. 2018;13:705–712.
   PubMed Web of Science ®Google Scholar
• Tripathi RKP, Ayyannan SR. Design, synthesis, and evaluation of 2-amino-6-nitrobenzothiazole-derived hydrazones as MAO inhibitors: role of the methylene spacer group. ChemMedChem. 2016;11:1551–1567.
   PubMed Web of Science ®Google Scholar
• Tripathi RKP, Rai GK, Ayyannan SR. Exploration of a library of 3,4-(methylenedioxy)aniline-derived semicarbazones as dual inhibitors of monoamine oxidase and acetylcholinesterase: design, synthesis, and evaluation. ChemMedChem. 2016;11:1145–1160.
   PubMed Web of Science ®Google Scholar
• Tripathi RKP, Sasi VM, Gupta SK, et al. Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site. J Enzyme Inhib Med Chem. 2018;33:37–57.
   PubMed Web of Science ®Google Scholar
• Ilgın S, Osmaniye D, Levent S, et al. Design and synthesis of new benzothiazole compounds as selective hMAO-B inhibitors. Molecules. 2017;22:2187.
   Web of Science ®Google Scholar
• Kaya B, Sağlık BN, Levent S, et al. Synthesis of some novel 2-substituted benzothiazole derivatives containing benzylamine moiety as monoamine oxidase inhibitory agents. J Enzyme Inhib Med Chem. 2016;31:1654–1661.
   PubMed Web of Science ®Google Scholar
• Nam M-H, Park M, Park H, et al. Indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson’s disease. ACS Chem Neurosci. 2017;8:1519−29.
   PubMed Web of Science ®Google Scholar
• Mathew B, Baek SC, Parambi DGT, et al. Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. Med Chem Commun. 2018;9:1871–1881.
   Google Scholar
• Çavuşoğlu BK, Sağlık BN, Osmaniye D, et al. Synthesis and biological evaluation of new thiosemicarbazone derivative Schiff bases as monoamine oxidase inhibitory agents. Molecules. 2018;23:60.
   Google Scholar
• Abid SMA, Aslam S, Zaib S, et al. Pyrazolobenzothiazine-based carbothioamides as new structural leads for the inhibition of monoamine oxidases: design, synthesis, in vitro bioevaluation and molecular docking studies. Med Chem Commun. 2017;8:452–464.
   Google Scholar
• Secci D, Bolasco A, Carradori S, et al. Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines. Eur J Med Chem. 2012;58:405–417.
   PubMed Web of Science ®Google Scholar
• Sağlık BN, Çavuşoğlu BK, Osmaniyea D, et al. In vitro and in silico evaluation of new thiazole compounds as monoamine oxidase inhibitors. Bioorg Chem. 2019;85:97–108.
   PubMed Web of Science ®Google Scholar
• D’Ascenzio M, Chimenti P, Gidaro MC, et al. (Thiazol-2-yl)hydrazone derivatives from acetylpyridines as dual inhibitors of MAO and AChE: synthesis, biological evaluation and molecular modeling studies. J Enzyme Inhib Med Chem. 2015;30:908–919.
   PubMed Web of Science ®Google Scholar
• Carradori S, Ortuso F, Petzer A, et al. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. Eur J Med Chem. 2018;143:1543–1552.
   PubMed Web of Science ®Google Scholar
• Secci D, Carradori S, Petzer A, et al. 4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis. J Enzyme Inhib Med Chem. 2019;34:597–612.
   PubMed Web of Science ®Google Scholar
• Secci D, Bolasco A, Chimenti P, et al. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents. Curr Med Chem. 2011;18:5114–5144.
   PubMed Web of Science ®Google Scholar
• Guglielmi P, Carradori S, Poli G, et al. Design, synthesis, docking studies and monoamine oxidase inhibition of a small library of 1-acetyl- and 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazoles. Molecules. 2019;24:484.
   PubMed Web of Science ®Google Scholar
• Evranos-Aksöz B, Yabanoğlu-Çiftçi S, Uçar G, et al. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies. Bioorg Med Chem Lett. 2014;24:3278–3284.
   PubMed Web of Science ®Google Scholar
• Badavath VN, Baysal İ, Uçar G, et al. Monoamine oxidase inhibitory activity of novel pyrazoline analogues: curcumin based design and synthesis. ACS Med Chem Lett. 2016;7:56−61.
   PubMed Web of Science ®Google Scholar
• Chen R, Xiao J, Ni Y, et al. Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: design, synthesis, model and use as hMAO-B inhibitors. Bioorg Med Chem. 2016;24:1741–1748.
   PubMed Web of Science ®Google Scholar
• Delport A, Harvey BH, Petzer A, et al. Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis. 2017;32:1357–1382.
   PubMed Web of Science ®Google Scholar
• Delport A, Harvey BH, Petzer A, et al. Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties. Life Sci. 2014;117:56–66.
   PubMed Web of Science ®Google Scholar
• Delport A, Harvey BH, Petzer A, et al. The monoamine oxidase inhibition properties of selected structural analogues of methylene blue. Toxicol Appl Pharmacol. 2017;325:1–8.
   PubMed Web of Science ®Google Scholar
• Delport A, Harvey BH, Petzer A, et al. Methylene blue analogues with marginal monoamine oxidase inhibition retain antidepressant-like activity. ACS Chem Neurosci. 2018;9:2917−28.
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Kochi A, Lin L, et al. Methyl yellow: a potential drug scaffold for Parkinson’s disease. ChemBioChem. 2014;15:1591–1598.
   PubMed Web of Science ®Google Scholar
• Wang X, Han C, Xu Y, et al. Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease. Molecules. 2017;22:1010.
   Web of Science ®Google Scholar
• Kallitsakis MG, Yañez M, Soriano E, et al. Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer’s disease. Future Med Chem. 2015;7:103–110.
   PubMed Web of Science ®Google Scholar
• Van der Walt MM, Terre’Blanche G, Petzer A, et al. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues. Bioorg Chem. 2015;59:117–123.
   PubMed Web of Science ®Google Scholar
• Chimenti F, Secci D, Bolasco A, et al. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009;52:1935–1942.
   PubMed Web of Science ®Google Scholar
• Yeon SK, Choi JW, Park J-H, et al. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson’s disease therapy. Bioorg Med Chem. 2018;26:232–244.
   PubMed Web of Science ®Google Scholar
• Engelbrecht I, Petzer JP, Petzer A. The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem Lett. 2015;25:1896–1900.
   PubMed Web of Science ®Google Scholar
• Mostert S, Petzer A, Petzer JP. Indanones as high-potency reversible inhibitors of monoamine oxidase. ChemMedChem. 2015;10:862–873.
   PubMed Web of Science ®Google Scholar
• Xiao X, Zhang -X-X, Zhan -M-M, et al. Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline. Eur J Med Chem. 2018;145:588–593.
   PubMed Web of Science ®Google Scholar
• Affini A, Hagenow S, Zivkovic A, et al. Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson’s disease. Eur J Med Chem. 2018;148:487–497.
   PubMed Web of Science ®Google Scholar
• Legoabe LJ, Petzer A, Petzer JP. The synthesis and evaluation of C7-substituted α-tetralone derivatives as inhibitors of monoamine oxidase. Chem Biol Drug Des. 2015;86:895–904.
   PubMed Web of Science ®Google Scholar
• Legoabe LJ, Petzer A, Petzer JP. α-Tetralone derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem Lett. 2014;24:2758–2763.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Wang H, et al. Design, synthesis and biological evaluation of 2-acetyl-5-O-(aminoalkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2017;27:5046–5052.
   PubMedGoogle Scholar
• Shen W, Yu S, Zhang J, et al. Synthesis and biological evaluation of 2-phenoxyacetamide analogues, a novel class of potent and selective monoamine oxidase inhibitors. Molecules. 2014;19:18620–18631.
   PubMed Web of Science ®Google Scholar
• Phillips OA, Sharaf LH, D’Silva R, et al. Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. Eur J Pharm Sci. 2015;71:56–61.
   PubMed Web of Science ®Google Scholar
• Phillips OA, D’Silva R, Bahta TO, et al. Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives. Eur J Med Chem. 2015;106:120–131.
   PubMed Web of Science ®Google Scholar
• Gunal SE, Tuncel ST, Kelekci NG, et al. Asymmetric synthesis, molecular modeling and biological evaluation of 5-methyl-3-aryloxazolidine-2,4-dione enantiomers as monoamine oxidase (MAO) inhibitors. Bioorg Chem. 2018;77:608–618.
   PubMed Web of Science ®Google Scholar
• Hicks JW, Sadovski O, Parkes J, et al. Radiosynthesis and ex vivo evaluation of [18F]-(S)-3-(6-(3-fluoropropoxy)benzo[d]isoxazol-3-yl)-5-(methoxymethyl)oxazolidin-2-one for imaging MAO-B with PET. Bioorg Med Chem Lett. 2015;25:288–291.
   PubMed Web of Science ®Google Scholar
• Chana HH, Tse MK, Kumar S, et al. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties. Eur J Pharmacol. 2018;818:254–262.
   PubMed Web of Science ®Google Scholar
• Chung JY, Lee JW, Ryu CH, et al. 1-[2-(4-Benzyloxyphenoxy)ehyl]imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson’s disease. J Neurosci Res. 2015;93:1267–1278.
   PubMed Web of Science ®Google Scholar
• Shetnev A, Osipyan A, Baykov S, et al. Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework. Bioorg Med Chem Lett. 2019;29:40–46.
   PubMed Web of Science ®Google Scholar
• Justo LA, Durán R, Alfonso M, et al. Effects and mechanism of action of isatin, a MAO inhibitor, on in vivo striatal dopamine release. Neurochem Int. 2016;99:147–157.
   PubMed Web of Science ®Google Scholar
• Guo B, Hu S, Zheng C, et al. Substantial protection against MPTP-associated Parkinson’s neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B. Neuropharmacol. 2017;126:12–24.
   PubMed Web of Science ®Google Scholar
• Denya I, Malan SF, Enogieru AB, et al. Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer’s disease. Med Chem Commun. 2018;9:357–370.
   Google Scholar
• Bautista-Aguilera OM, Samadi A, Chioua M, et al. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)‑1H‑indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J Med Chem. 2014;57:10455−63.
   PubMed Web of Science ®Google Scholar
• Bautista-Aguilera ÓM, Hagenow S, Palomino-Antolin A, et al. Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases. Angew Chem Int Ed. 2017;56:12765–12769.
   PubMed Web of Science ®Google Scholar
• Tzvetkov NT, Stammler H-G, Neumann B, et al. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem. 2017;127:470–492.
   PubMed Web of Science ®Google Scholar
• Tzvetkov NT, Stammler H-G, Hristova S, et al. (Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons. Eur J Med Chem. 2019;162:793–809.
   PubMed Web of Science ®Google Scholar
• Lan J-S, Liu Y, Hou J-W, et al. Design, synthesis and evaluation of resveratrol-indazole hybrids as novel monoamine oxidases inhibitors with amyloid-β aggregation inhibition. Bioorg Chem. 2018;76:130–139.
   PubMed Web of Science ®Google Scholar
• Bar-Ama O, Amit T, Kupershmidt L, et al. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson’s disease and aging. Neurobiol Aging. 2015;36:1529–1542.
   PubMed Web of Science ®Google Scholar
• Wang L, Esteban G, Ojima M, et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem. 2014;80:543–561.
   PubMed Web of Science ®Google Scholar
• Khan NA, Khan I, Abid SMA, et al. Quinolinic carboxylic acid derivatives as potential multi-target compounds for neurodegeneration: monoamine oxidase and cholinesterase inhibition. Med Chem. 2018;14:74–85.
   PubMed Web of Science ®Google Scholar
• Meiring L, Petzer JP, Petzer A. C6- and C7-substituted 3,4-dihydro-2(1H)-quinolinones as inhibitors of monoamine oxidase. Drug Res (Stuttg). 2017;67:170–178.
   PubMed Web of Science ®Google Scholar
• Sang Z, Pan W, Wang K, et al. Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2017;25:3006–3017.
   PubMed Web of Science ®Google Scholar
• Pesarico AP, Sampaio TB, Stangherlin EC, et al. The antidepressant-like effect of 7-fluoro-1,3-diphenylisoquinoline-1-amine in the mouse forced swimming test is mediated by serotonergic and dopaminergic systems. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;54:179–186.
   PubMed Web of Science ®Google Scholar
• Sampaio TB, Da Rocha JT, Prigol M, et al. 4-Organoseleno-isoquinolines selectively and reversibly inhibit the cerebral monoamine oxidase B activity. J Mol Neurosci. 2016;59:135–145.
   PubMed Web of Science ®Google Scholar
• Qhobosheane MA, Legoabe LJ, Petzer A, et al. The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone. Bioorg Chem. 2019;85:60–65.
   PubMed Web of Science ®Google Scholar
• Qhobosheane MA, Petzer A, Petzer JP, et al. Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2018;26:5531–5537.
   PubMedGoogle Scholar
• Bacho M, Coelho-Cerqueira E, Follmer C, et al. A medical approach to the monoamine oxidase inhibition by using 7H-benzo[e]perimidin-7-one derivatives. Curr Top Med Chem. 2017;17:489–497.
   PubMed Web of Science ®Google Scholar
• Abbas N, Zaib S, Bakht SM, et al. Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: synthesis, in vitro biological evaluation and molecular modelling analysis. Bioorg Chem. 2017;70:17–26.
   PubMed Web of Science ®Google Scholar
• Çavuşoğlu BK, Sağlık BN, Özkay Y, et al. Design, synthesis, monoamine oxidase inhibition and docking studies of new dithiocarbamate derivatives bearing benzylamine moiety. Bioorg Chem. 2018;76:177–187.
   PubMed Web of Science ®Google Scholar
• Altintop MD, Sever B, Osmaniye D, et al. Design, synthesis, in vitro and in silico evaluation of new pyrrole derivatives as monoamine oxidase inhibitors. Arch Pharm Chem Life Sci. 2018;351:e1800082.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Wang H, et al. Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2017;27:5053–5059.
   PubMed Web of Science ®Google Scholar
• Kumar B, Sheetal, Mantha AK, et al. Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors. Bioorg Chem. 2018;77:252–262.
   PubMed Web of Science ®Google Scholar
• Saddique FA, Zaib S, Jalil S, et al. Synthesis, monoamine oxidase inhibition activity and molecular docking studies of novel 4-hydroxy-N’-[benzylidene or 1-phenylethylidene]-2-H/methyl/benzyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides. Eur J Med Chem. 2018;143:1373–1386.
   PubMed Web of Science ®Google Scholar
• Santillo MF. Inhibition of monoamine oxidase (MAO) by α-ethylphenethylamine and N,α-diethylphenethylamine, two compounds related to dietary supplements. Food Chem Toxicol. 2014;74:265–269.
   PubMed Web of Science ®Google Scholar
• Carradori S, D’Ascenzio M, Chimenti P, et al. Selective MAO-B inhibitors: a lesson from natural products. Mol Div. 2014;18:219–243.
   PubMed Web of Science ®Google Scholar
• Zhi -K-K, Yang Z-D, Shi D-F, et al. Desmodeleganine, a new alkaloid from the leaves of Desmodium elegans as a potential monoamine oxidase inhibitor. Fitoterapia. 2014;98:160–165.
   PubMed Web of Science ®Google Scholar
• De Monte C, Carradori S, Chimenti P, et al. New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies. Eur J Med Chem. 2014;82:164–171.
   PubMed Web of Science ®Google Scholar
• Mohamed EI, Zaki MA, Chaurasiya ND, et al. Monoamine oxidases inhibitors from Colvillea racemosa: isolation, biological evaluation, and computational study. Fitoterapia. 2018;124:217–223.
   PubMed Web of Science ®Google Scholar
• Carradori S, Gidaro MC, Petzer A, et al. Inhibition of human monoamine oxidase: biological and molecular modeling studies on selected natural flavonoids. J Agric Food Chem. 2016;64:9004–9011.
   PubMed Web of Science ®Google Scholar
• Gidaro MC, Astorino C, Petzer A, et al. Kaempferol as selective human MAO-A inhibitor: analytical detection in Calabrian red wines, biological and molecular modelling studies. J Agric Food Chem. 2016;64:1394–1400.
   PubMed Web of Science ®Google Scholar
• Lee HW, Ryu HW, Baek SC, et al. Potent inhibitions of monoamine oxidase A and B by acacetin and its 7-O-(6-O-malonylglucoside) derivative from Agastache rugosa. Int J Biol Macromol. 2017;104:547–553.
   PubMed Web of Science ®Google Scholar
• Zarmouh NO, Mazzio EA, Elshami FM, et al. Evaluation of the inhibitory effects of Bavachinin and Bavachin on human monoamine oxidases A and B. Evid Based Complement Alternat Med. 2015;2015:14. Article ID 852194.
   Web of Science ®Google Scholar
• Zarmouh NO, Messeha SS, Elshami FM, et al. Evaluation of the isoflavone Genistein as reversible human monoamine oxidase-A and -B inhibitor. Evid Based Complement Alternat Med. 2016;2016:12. Article ID 1423052.
   Web of Science ®Google Scholar
• Chaurasiya ND, Gogineni V, Elokely KM, et al. Isolation of Acacetin from Calea urticifolia with inhibitory properties against human monoamine oxidase-A and –B. J Nat Prod. 2016;79:2538−44.
   PubMed Web of Science ®Google Scholar
• Khamphukdee C, Monthakantirat O, Chulikhit Y, et al. Chemical constituents and antidepressant-like effects in ovariectomized mice of the ethanol extract of Alternanthera philoxeroides. Molecules. 2018;23:2202.
   Web of Science ®Google Scholar
• Zarmouh NO, Eyunni SK, Soliman KFA. The benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor. BMC Complement Altern Med. 2017;17:34.
   PubMed Web of Science ®Google Scholar
• Lee HW, Ryu HW, Kang M-G, et al. Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens. Bioorg Med Chem Lett. 2016;26:4714–4719.
   PubMed Web of Science ®Google Scholar
• Basu M, Mayana K, Xavier S, et al. Effect of scopoletin on monoamine oxidases and brain amines. Neurochem Int. 2016;93:113–117.
   PubMed Web of Science ®Google Scholar
• Khatri DK, Juvekar AR. Kinetics of inhibition of monoamine oxidase using curcumin and ellagic acid. Pharmacogn Mag. 2016;12:S116–S120.
   PubMed Web of Science ®Google Scholar
• Chaurasiya ND, León F, Ding Y, et al. Interactions of desmethoxyyangonin, a secondary metabolite from Renealmia alpinia, with human monoamine oxidase-A and oxidase-B. Evid Based Complement Alternat Med. 2017;2017:10. Article ID 4018724.
   Web of Science ®Google Scholar
• Lee HW, Choi H, Nam S-J, et al. Potent inhibition of monoamine oxidase B by a piloquinone from marine-derived Streptomyces sp. CNQ-027. J Microbiol Biotechnol. 2017;27:785–790.
   PubMed Web of Science ®Google Scholar
• Son B, Jun SY, Seo H, et al. Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer. Sci Rep. 2016;6:21986.
   PubMed Web of Science ®Google Scholar
• Wu G-F, Jiang X-L, Gong Y-Z, et al. Ligand fishing of anti-neurodegenerative components from Lonicera japonica using magnetic nanoparticles immobilised with monoamine oxidase B. J Sep Sci. 2019;42:1–10.
   Web of Science ®Google Scholar
• Mocan A, Diuzheva A, Carradori S, et al. Development of novel techniques to extract phenolic compounds from Romanian cultivars of Prunus domestica L. and their biological properties. Food Chem Toxicol. 2018;119:189–198.
   PubMed Web of Science ®Google Scholar
• Chaurasiya ND, Ibrahim MA, Muhammad I, et al. Monoamine oxidase inhibitory constituents of propolis: kinetics and mechanism of inhibition of recombinant human MAO-A and MAO-B. Molecules. 2014;19:18936–18952.
   PubMed Web of Science ®Google Scholar
• Ademosun O, Adebayo AA, Oboh G. Modulatory effect of some citrus (Citrus limon, Citrus reticulata, Citrus maxima) peels on monoamine oxidase, phosphodiesterase-5 and angiotensin-1 converting enzyme activities in rat heart homogenate. J Complement Integr Med. 2018;2018:20180067.
   Google Scholar
• Medina-Franco JL, Giulianotti MA, Welmaker GS, et al. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today. 2013;18:495–501.
   PubMed Web of Science ®Google Scholar
• Ramsay RR. Molecular aspects of monoamine oxidase B. Prog Neuropsychopharmacol Biol Psychiatry. 2016;69:81–89.
   PubMed Web of Science ®Google Scholar
• De Monte C, D’Ascenzio M, Guglielmi P, et al. Opening new scenarios for human MAO inhibitors. Cent Nerv Syst Agents Med Chem. 2016;16:98–104.
   PubMedGoogle Scholar
• Shih JC. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy. J Neural Transm. 2018;125:1553–1566.
   PubMed Web of Science ®Google Scholar